Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)

Trial Profile

Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs MEDI 0457 (Primary)
  • Indications Head and neck cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2017 Results presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 2017, according to an Inovio Pharmaceuticals media release.
    • 11 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top